Dysregulation of Host Cellular microRNA Expression by the Human Papillomavirus E6 and E7 Oncoproteins

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citable link: http://nrs.harvard.edu/urn-3:HUL.InstRepos:40046534

Terms of Use: This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
<table>
<thead>
<tr>
<th>miR</th>
<th>Accession</th>
<th>Sequence</th>
<th>Status</th>
<th>Tissue and Cancer Types</th>
<th>PMIDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>43</td>
<td>miR-221</td>
<td>hsa-miR-221-3p</td>
<td>agcuacaauugcugcuggguucc</td>
<td>YES</td>
<td>hepatocellular carcinoma, prostate cancer, NSCLC, ovarian cancer, gastric cancer</td>
</tr>
<tr>
<td>44</td>
<td>miR-222</td>
<td>hsa-miR-222-3p</td>
<td>agcuacaacugcugcuggguu</td>
<td>YES</td>
<td>acute lymphoblastic leukemia, ESCC (x2), hepatocellular carcinoma (x2), NSCLC (x3), gastric cancer, breast cancer</td>
</tr>
<tr>
<td>45</td>
<td>miR-223</td>
<td>hsa-miR-223-3p</td>
<td>ugcucguuugcuauuccacccca</td>
<td>YES</td>
<td>pancreatic cancer, breast cancer, ovarian cancer</td>
</tr>
<tr>
<td>46</td>
<td>miR-25</td>
<td>hsa-miR-25-3p</td>
<td>cauugcaccucugcuggugu</td>
<td>YES</td>
<td>ESCC (x2), gastric cancer</td>
</tr>
<tr>
<td>47</td>
<td>miR-26a</td>
<td>hsa-miR-26a-5p</td>
<td>uucuagcauucaggaauagc</td>
<td>YES</td>
<td>hepatocellular carcinoma, ovarian cancer (x2)</td>
</tr>
<tr>
<td>49</td>
<td>miR-29a</td>
<td>hsa-miR-29a-3p</td>
<td>uagccaccaucugaaaucgguua</td>
<td>YES</td>
<td>colorectal cancer (x5), breast cancer, ovarian cancer</td>
</tr>
<tr>
<td>50</td>
<td>miR-29b</td>
<td>hsa-miR-29b-3p</td>
<td>uagccaccauuugaaaucagu</td>
<td>YES</td>
<td>potential normalizer</td>
</tr>
<tr>
<td>51</td>
<td>miR-30a</td>
<td>hsa-miR-30a-3p</td>
<td>uaaagcugguugagagggcga</td>
<td>YES</td>
<td>colon cancer</td>
</tr>
<tr>
<td>52</td>
<td>miR-30c</td>
<td>hsa-miR-30c-3p</td>
<td>uaaagcugguugagagggcga</td>
<td>YES</td>
<td>breast cancer, colorectal cancer</td>
</tr>
<tr>
<td>53</td>
<td>miR-335</td>
<td>hsa-miR-335-5p</td>
<td>ucaagagcaauaacgaaaaaugu</td>
<td>YES</td>
<td>NSCLC (x2), mesothelioma, colorectal cancer</td>
</tr>
<tr>
<td>54</td>
<td>miR-34a</td>
<td>hsa-miR-34a-5p</td>
<td>ugggcuguucuauugguguu</td>
<td>YES</td>
<td>multiple myeloma, DLBCL, breast cancer, colorectal cancer, gastric cancer</td>
</tr>
<tr>
<td>55</td>
<td>miR-34b</td>
<td>hsa-miR-34b-3p</td>
<td>ccaacucuaacucuagcuaau</td>
<td>NO</td>
<td>osteosarcoma</td>
</tr>
<tr>
<td>56</td>
<td>miR-375</td>
<td>hsa-miR-375-3p</td>
<td>uuuugcugcuugguccugcguag</td>
<td>YES</td>
<td>prostate cancer, ESCC (x2), pancreatic cancer (x2), NSCLC (x2), breast cancer</td>
</tr>
<tr>
<td>57</td>
<td>miR-376c</td>
<td>hsa-miR-376c-3p</td>
<td>ccacuagggagaaauuccacc</td>
<td>NO</td>
<td>breast cancer (x2), gastric cancer</td>
</tr>
<tr>
<td>58</td>
<td>miR-378</td>
<td>hsa-miR-378a-3p</td>
<td>acuggacucggacagaagggc</td>
<td>NO</td>
<td>colorectal cancer, gastric cancer</td>
</tr>
<tr>
<td>59</td>
<td>miR-379</td>
<td>hsa-miR-379-3p</td>
<td>ucuacacgcagcggccatt</td>
<td>YES</td>
<td>breast cancer (x2)</td>
</tr>
<tr>
<td>60</td>
<td>miR-451</td>
<td>hsa-miR-451a-3p</td>
<td>uaaaccguuaccaauacagu</td>
<td>NO</td>
<td>ESCC, breast cancer, ovarian cancer</td>
</tr>
<tr>
<td>61</td>
<td>miR-483-5p</td>
<td>hsa-miR-483-5p</td>
<td>uagacgguaggagaaagaagggag</td>
<td>NO</td>
<td>potential hemolysis marker, colon cancer, breast cancer, gastric cancer (x2)</td>
</tr>
<tr>
<td>62</td>
<td>miR-486</td>
<td>hsa-miR-486-5p</td>
<td>uccuguacagcucgcggcag</td>
<td>YES</td>
<td>prostatic cancer, ESCC (x2), colorectal cancer (x2), NSCLC (x2), prostate cancer, lung cancer, breast cancer</td>
</tr>
<tr>
<td>63</td>
<td>miR-574</td>
<td>hsa-miR-574-3p</td>
<td>caccucgcuagcacaaccacca</td>
<td>YES</td>
<td>prostate cancer, NSCLC, breast cancer</td>
</tr>
<tr>
<td>64</td>
<td>miR-625-3p</td>
<td>hsa-miR-625-3p</td>
<td>gacuacaagacauucucucccuca</td>
<td>NO</td>
<td>mesothelioma, lung cancer</td>
</tr>
<tr>
<td>65</td>
<td>miR-652</td>
<td>hsa-miR-652-3p</td>
<td>auaggcgccacuaggggug</td>
<td>YES</td>
<td>breast cancer (x2), colorectal cancer</td>
</tr>
<tr>
<td>66</td>
<td>miR-9</td>
<td>hsa-miR-9-5p</td>
<td>ucuuaggguuauucacuguaug</td>
<td>YES</td>
<td>endometrial carcinoma</td>
</tr>
</tbody>
</table>
miR-93-5p | hsa-mir-93-5p | caaagugcuguucgucaguag | YES | acute myeloid leukemia, NSCLC, breast cancer (x2), ovarian cancer |
---|---|---|---|---|
68 | x-control | x-control | x-control | N/A | internal reference |
69 | blank | blank | none | N/A | internal reference |

**References**


